Skip to main content

Table 1 Selected targeted agents for ovarian cancer evaluated in phase II studies*

From: Safe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs

Targeted molecular agents

Primary molecular target

FDA approved cancer sites

Response rate in ovarian cancer

Toxicities

Imatinib

KIT, PDGF-R (TKI)

GIST

0% ORR, 33% SD [20, 21]

Fatigue, diarrhea, rash, nausea, cardiotoxicity, granulocytopenia

Trastuzumab

HER-2 (mAB)

Breast, gastroeosphageal

7.3% ORR [22]

Fatigue, diarrhea, rash, cardiotoxicity, anemia, dyspnea, neutropenia

Pertuzumab

HER-2 (TKI)

Breast cancer

4.3% ORR, 6.8% SD [23]

Diarrhea, neutropenia, nausea, LV dysfunction, VTE, vomiting, renal failure

Bevacizumab

VEGF (mAB)

Glioblastoma, NSCLC, mBreast, mCRC, mRCC

15-21% ORR, 25-52% SD [24, 25]

Fatigue, diarrhea, anorexia, hypertension, gastrointestinal perforation, proteinuria, hemorrhage, congestive heart failure, arterial thromboembolism, wound healing problems

Gefitinib

EGFR (TKI)

NSCLC

0-4% ORR, 29-37% SD [26–28]

Diarrhea, rash, nausea, vomiting, mucositis, dyspnea

Erlotinib

EGFR (TKI)

NSCLC

6% ORR, 44% SD [29]

Fatigue, diarrhea, rash, anorexia

Temsirolimus

mTOR inhibitor

RCC

9.3% ORR, 24.1% 6m PFS [30]

Fatigue, diarrhea, rash, nausea, anorexia, stomatitis, anemia, hypertension, dyspnea

Vandetanib

EGFR, TEGF, RET (TKI)

Medullary thyroid cancer

0% ORR/SD [31]

Diarrhea, rash, hypertension, proteinuria, asymptomatic, QT prolongation

Sorafenib

VEGF, PDGF, c-Raf (TKI, Raf KI)

RCC, hepatocellular carcinoma

3% ORR, 34% SD [32]

Fatigue, diarrhea, rash, nausea, vomiting, anorexia, hypothyroidism, cardiotoxicity, hand–foot syndrome

Sunitinib

VEGF, PDGF, KIT (TKI)

RCC, GIST, pancreatic neuroendocrine tumor

3% ORR, 53% SD [33]

Fatigue, diarrhea, nausea, vomiting, hypothyroidism, hypertension, cardiotoxicity

Pazopanib

TKI VEGF, PDGFR (TKI)

RCC, soft tissue sarcoma

31% ORR, 56% SD (Ca-125 response) [34]

Fatigue, diarrhea, nausea, anorexia, hypertension, abdominal pain, arrhythmia, hepatotoxicity, hemorrhage

Lapatinib

HER2, EGFR (TKI)

Breast Cancer

0% ORR, 8 SD [35]

QT prolongation, CYP3A4, GI toxicity

Olaparib

PARP inbibitor

n/a

24-41% ORR, 35%-59% SD (BRCA carriers) [36, 37]

fatigue, somnolence, nausea, loss of appetite, thrombocytopenia

  1. *There are no FDA approved targeted agents in ovarian cancer.
  2. Abbreviations: TKI = tyrosine kinase inhibitor, mAB (monoclonal antbody), mTOR (mammalian target of rapamycin), PARP (Poly ADP-ribose polymerase), GIST (Gastrointestinal stromal tumor), NSCLC (non-small cell lung cancer), CRC (colorectal cancer), RCC (renal cell carcinoma), m (metastatic), ORR (overall response rate, REIST criteria if not specified), SD (stable disease).